Opposite Effects of Methanandamide on Lipopolysaccharide-Induced Prostaglandin E2 and F2α Synthesis in Uterine Explants from Pregnant Mice

Claudia A. Vercelli∗, Julieta Aisemberg, Maximiliano Cella, Ana Inés Salazar, Manuel L. Wolfson, Ana M. Franchi

Laboratory of Physiopathology of Pregnancy and Labor, Center for Pharmacological and Botanical Studies (National Research Council – School of Medicine, University of Buenos Aires), Ciudad Autónoma de Buenos Aires (CABA), Buenos Aires, Argentina

Abstract

Prostaglandins (PG) are effective abortifaciants and are important mediators of lipopolysaccharide (LPS)-induced embryonic resorption (ER). Besides, anandamide (AEA) has been described as one of the major endocannabinoids present in the uterus suggesting that it might play a role in reproduction. It has been reported that high levels of AEA are associated with pregnancy failure and that LPS increases AEA production. Also, it has been observed that AEA modulates PG production in different tissues. In this sense, we studied whether LPS-induced PG production is modulated by AEA and we also assessed the effect of this endocannabinoid on PG metabolism in an in vitro model. Uterine explants from BALB/c implantation sites were cultured in the presence of LPS plus cannabinoid receptor (CB) specific antagonists and PG production was assessed. Then, we studied the effect of exogenous AEA on different steps of PG metabolic pathway. We showed that AEA is involved in LPS-induced PG biosynthesis. Also, we observed that AEA exerts opposite effects on PGF2α and PGF2α biosynthesis, by inhibiting PGF2α production and increasing PGF2α levels. We suggest that AEA could be involved in the mechanisms implicated in LPS-induced ER. A better understanding of how AEA could be affecting ER could help developing specific interventions to prevent this pathology.

Introduction

Intrauterine infection plays a major role in the pathogenesis of early pregnancy loss. It has been reported that Gram-negative organisms induce preterm labor and embryonic loss by triggering the release of various proinflammatory molecules, such as cytokines, growth factors and prostaglandins [1,2,3]. Prostaglandins are important paracrine regulators of uterine function in normal and pathological pregnancies and are used clinically to induce abortion and stimulate parturition [4]. Our previous results [1] showed that in vivo administration of lipopolysaccharide (LPS), a component of Gram-negative bacteria, increased prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) production in the uterus of early pregnant mice. We have also observed that, in mice challenge with LPS, the in vivo administration of cyclooxygenase (COX) inhibitors prevented LPS-induced embryonic resorption (ER).

Anandamide (arachidonylethanolamide, AEA) belongs to a group of endogenous lipids termed “endocannabinoids” [5] and is an agonist of type-1 (CB1) and type-2 (CB2) cannabinoid receptors. It has been described as one of the major endocannabinoids present in the uterus and this suggests that it might play a role in reproduction [6]. It has been reported that low levels of AEA are beneficial for implantation and trophoblast outgrowth while increased AEA concentrations are associated with retarded embryo development, fetal loss and pregnancy failure [7]. Previous results indicate that LPS increases AEA levels in human peripheral lymphocytes [8] and in murine macrophages [9]. Our previous results suggest that LPS could be increasing AEA levels in uterine explants by inhibiting its degradation and also by enhancing NAPE-PLD expression, one of its synthesizing enzymes [10]. In addition, recent research has revealed that AEA regulates prostaglandin production in human gestational tissues, cerebral microvascular endothelium and in rat pheochromocytoma PC12 cells [11,12,13]. Although several lines of evidence indicate that both, cannabinoids and AEA, stimulate arachidonic acid (AA) release in several tissues [14,15,16], the relationship between endocannabinoids and PG metabolism is not fully understood. In the present study we investigated whether LPS-induced PG production is modulated by AEA and we also determined the effect of this endocannabinoid on PG biosynthesis and catabolism in uterine explants from pregnant mice.
Materials and Methods

Animals

BALB/c 8- to 12-week-old virgin female mice were paired with 8- to 12-week-old BALB/c males and the day of appearance of a coital plug was taken as day 0 of pregnancy. Animals were housed in cages under controlled conditions of light (14 h light, 10 h dark) and temperature (23–25°C) and received murine chow and water ad libitum. Mice were sacrificed by cervical dislocation on day 7 of pregnancy and in each implantation site the uterus and the decidua were separated. Uterine explants (composed of myometrial cells and uterine adventitia) were weighed and cultured as described below.

Ethics Statement

The experimental procedures reported here were approved by the Animal Care Committee of the Center for Pharmacological and Botanical Studies of the National Research Council (CEFYBO - CONICET) and were carried out in accordance with the Guide for Care and Use of Laboratory Animals (NIH).

Culture of Uterine Explants from Implantation Sites

We established the optimal culture conditions in a previous work [10]. Briefly, uterine explants were weighed and cultured in wells that contained DMEM supplemented with 10% FCS and 1% antibiotic-antimycotic solution. Tissues were maintained for 24 h in 5% CO2 in air at 37°C and then culture supernatants and explants were immediately frozen at –70°C until use.

![Figure 1. LPS-induced PGE2 and PGF2α production is mediated by endocannabinoids. A) PGE2 production for uterine explants incubated with LPS (1 µg/ml) and AM251 (10 nM) or SR144528 (10 nM) for 24 h. ANOVA test, a, p<0.001 vs control or AM251 or SR144528; b, p<0.001 vs control or AM251; c, p<0.001 vs LPS. n = 6. B) PGF2α production for uterine explants incubated with LPS (1 µg/ml) and AM251 (10 nM) or SR144528 (100 nM) for 24 h. ANOVA test, a, p<0.001 vs control or AM251 or SR144528; b, p<0.01 vs control or AM251; c, p<0.001 vs control or SR144528; d, p<0.001 vs LPS; e, p<0.01 vs LPS. n = 5.

doi:10.1371/journal.pone.0039532.g001]
Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis
cDNA was synthesized from total RNA as described by Vercelli et al. [10]. Oligonucleotide primers for COX-1, COX-2 and β-actin were synthesized as described by Aisemberg et al. [1] and PCR cycle parameters were described in the same work. Oligonucleotide primers for CB1 were 5’-ACCTGATGTCTGTGATCGGA-3’ (forward) and 5’-TGTTATCTAGAGGCTGCGCA-3’ (reverse) and for CB2 were 5’-CCGGAAAAGAGGATGGCAATGAAT-3’ (forward) and 5’-CTGCTGAGCGCCCTGGAGAAC-3’ (reverse). Oligonucleotide primers for mPGES-1, mPGES-2 and cPGES were synthesized using Primer 3 Input free Software (v 0.4.0) [17]. For mPGES-1, 5’-GGGTCCCAGGAATGAGTACA-3’ (forward) and 5’-CACCTGAGGATGATCGTG-3’ (reverse) were used; and for cPGES, 5’-AAAAATCGCCGATGACAACGTCG-GAGLAACTGGAGGATG-3’ (reverse) were used. PCR products (COX-1, 449 bp; COX-2, 320 bp; β-actin, 392 bp; CB1, 450 bp; CB2, 479 bp; mPGES-1, 237 bp; mPGES-2, 201 bp and cPGES, 194 bp) were separated on 1.5% agarose gel, stained with ethidium bromide, recorded under UV light with a digital camera Olympus C-5060 and analysed using the Image J software package (open source). Data were expressed as the relative amount of each PCR product versus β-actin mRNA.

Quantitative Polymerase Chain Reaction (qPCR) Analysis
cDNA was synthesized from total RNA as described by Vercelli et al. [10]. Real-time quantitative PCR was performed with a Corbett-Rotor Gene system (Qiagen, Argentina) using

Figure 2. AEA mediates LPS-induced PG production. A) PGE₂ production for uterine explants incubated with LPS (1 ug/ml), m-AEA (100 nM), URB597 (1 uM), LPS plus m-AEA (100 nM) or LPS plus URB597 (1 uM) for 24 h. ANOVA test. a, p<0.001 vs control; b, p<0.01 vs LPS; c, p<0.001 vs LPS. n=7. B) PGF₂α production for uterine explants incubated with LPS (1 ug/ml), m-AEA (100 nM), URB597 (1 uM), LPS plus m-AEA (100 nM) or LPS plus URB597 (1 uM) for 24 h. ANOVA test. a, p<0.001 vs control; b, p<0.01 vs LPS; c, p<0.05 vs control; d, p<0.01 vs control. n=7.
doi:10.1371/journal.pone.0039532.g002
EVA green (Biotium Inc., CA, USA) as the detection agent. Oligonucleotide primers for m-PGES-1 and β-actin were synthesized as described by Kubota et al. [18] and by Wang et al. [19], respectively. Specificity of the PCR reaction was controlled by the generation of melting curves. The relative gene expression levels were calculated using the comparative Ct (ΔΔCt) method [20]. Data was normalized to β-actin and mPGES-1 mRNA levels under control conditions (no m-AEA) were set to 1 (dotted line). Experiments were independently run three times. In each experiment, cDNA samples were performed in triplicate.

Western Blot Analysis

Tissues were homogenized and centrifuged as described by Vercelli et al. [21]. Samples were separated by electrophoresis and transferred to a nitrocellulose membrane. Blots were incubated overnight with the primary antibodies and 30 minutes with anti-β-actin, washed with buffer (10 mM Tris, 100 mM NaCl and 0.1% Tween 20, pH 7.5) followed by 1 h incubation with horse radish peroxidase-conjugated anti-rabbit secondary antibody, and developed using the enhanced chemiluminescence western blot system. Photographs of the membranes were taken using a digital camera and analysed using the Image J software package.

PGE$_2$ and PGF$_{2\alpha}$ Determination

The amount of PGE$_2$ and PGF$_{2\alpha}$ were assayed in culture supernatants by specific radioimmunoassay (RIA) as reported by Farina et al. [22]. Briefly, specific antisera for both PGF$_{2\alpha}$ and PGE$_2$ were used. Labelled [$^3$H]-PGE$_2$ and [$^3$H]-PGF$_{2\alpha}$ were added to each tube. The incubation was performed for 90 min at 4°C. Bound and free radioisotopes were separated by dextran-coated charcoal and the tubes were centrifuged for 15 min at 2000×g. Results were expressed as pg PG/mg tissue (wet weight).

Quantification of PGE$_2$ metabolite (PGEM)

PGE$_2$ metabolite was assayed in culture supernatants with the PGE metabolite EIA kit (catalog No. 14531; Cayman Chemical Co) according to the manufacturer’s recommendations. PGE$_2$ is not chemically stable and is rapidly converted to its 13,14-dihydro-15-keto metabolite. The PGE metabolite assay kit converts all of the immediate PGE$_2$ metabolites in the supernatant to a single stable derivative that could be easily quantified by EIA. PGEM levels are reported as pg PGEM/mg tissue (wet weight).

Determination of PGE Synthase (PGES) Activity

PGES activity in uterine explants was measured by assessment of conversion of PGH$_2$ to PGE$_2$ as reported by Murakami et al. [23] with minor modifications. Briefly, tissues were
homogenized in a 10 mM Tris-HCl buffer (pH = 8) and after centrifugation the supernatants were used as the enzyme source. One hundred micrograms of protein were incubated with 2 μg of PGH2 for 1 min at 24°C in 0.1 ml of 1 M Tris-HCl, pH = 8, containing 2 mM GSH. After terminating the reaction by the addition of 20 ul of HCl 6N, PGE2 content in the supernatants was quantified by radioimmunoassay. Results were expressed as pg PGE2/mg protein/h.

COX-2 Enzyme Activity Determination

COX-2 activity was determined by measuring the disappearance of the radiolabelled substrate [14C]-arachidonic acid using a modified method previously reported [24]. Briefly, 100 mg of uterine explants were homogenized in 1 ml cold fresh buffer (50 mM Tris-HCl and 1 mM EDTA, pH = 8), centrifuged at 20000 x g for 60 min at 4°C and supernatant was used for subsequent determination of enzyme activity. One hundred micrograms of protein were added to each incubation tube in

Figure 4. LPS-induced COX-2 expression is mediated by endocannabinoids. Densitometric analysis of A) mRNA and B) protein expression of COXs. Uterine explants were incubated with LPS alone (1 ug/ml), LPS plus AM251 (10 nM) or LPS plus SR144528 (10 nM) for 24 h. A) ANOVA test. a, p<0.001 vs control; b, p<0.001 vs LPS; c, p<0.01 vs control; d, p<0.05 vs control. n = 5. B) ANOVA test. a, p<0.001 vs control; b, p<0.001 vs LPS; n = 4. One representative gel/blot is shown.
doi:10.1371/journal.pone.0039532.g004
cold fresh buffer to a final volume of 100 ul containing 110,000 d.p.m [14C]-arachidonic acid (AA, specific activity 53 mCi/mmole), either alone or with a selective COX-2 inhibitor (NS-398 1mM). The sample and substrate mixture with a non-selective COX inhibitor (Indomethacin, [INDO] 1mM) was used to determine the [14C]-AA disappearance values due to other enzymatic activities (lipoxygenase and/or epoxygenase) and non-enzymatic reactions [25]. The mixture was then incubated at 37°C for 30 min. Termination was achieved by addition of chloroform:methanol (1:1, v/v). The unreacted [14C]-AA was resolved in the organic layer of a solvent system of ethyl acetate:hexane:acetic acid:distilled water (100:50:20:100 v/v) mixture. The distribution of radioactivity on the plate was counted in a scintillation counter by scraping off the corresponding spots detected in the plate. The area of each radioactive peak corresponding to AA was calculated and expressed as a percentage of the total radioactivity of the plates. For each sample, COX-1 activity was determined by calculating the rate of loss of [14C]-AA incubated with selective COX-2 inhibitor. Conversely, the COX-2 activity of each corresponding sample was determined by calculating the rate of loss of [14C]-AA incubated without selective COX-2 inhibitor, and subtracting from this value that of COX-1. The values of COX-2 and COX-1 were corrected by subtracting the [14C]-AA disappearance values due to other enzymatic activities and non-enzymatic reactions. Enzyme activity is reported as nmol of disappeared [14C]-AA/mg protein/h. The optimal reaction conditions were previously determined (data not shown).

Drugs, Chemical Reagents and Other Materials

LPS from Escherichia coli 05:B55, secondary horse radish peroxidase (HRP) conjugated antibody, anti-β-actin antibody, R(+)-methanandamide, NADPH, and GSH were purchased from Sigma Chemical Co. (St Louis, MI, USA). AM251 was purchased from Tocris Cookson Inc. (Ellisville, MO, USA). SR144528 was kindly provided by Sanofi-Aventis. Indomethacin was obtained from Laboratorios Montpellier (Bs As, Argentina). TLC aluminum Silica Gel plates were purchased from Merck KGaA (Darmstadt, Germany). Western blotting reagents were obtained from Bio-Rad Laboratory. Anti-COX-1 and anti-COX-2 antibodies, PGH2, URB597 and Prostaglandin E Metabolite EIA kit were purchased from Cayman Chemical Co (Ann Arbor, MI, USA). The anti-mPGES-1 antibody was obtained from BD Biosciences (Franklin Lakes, NJ, USA). All other chemicals were analytical grade.

Data Analysis and Statistical Procedures

Statistical analysis was performed using the Graph Pad Prism Software (San Diego, CA, USA). Comparisons between values of different groups were performed using one-way ANOVA. Significance was determined using Tukey’s multiple comparison tests for unequal replicates or Student t Test. All values presented in this study represent means ± SEM. Differences between means were considered significant when p was 0.05 or less.

Results

LPS-induced PGE2 and PGF2α Production is Mediated by Endocannabinoids

As mentioned before, previous results showed that in vivo administration of LPS increased PGE2 and PGF2α production in the uterus of early pregnant mice [1]. Figure 1 (A and B) shows that uterine explants incubated for 24 h in the presence of LPS (1 μg/ml) induced PGE2 and PGF2α production in vitro. To evaluate whether endogenous cannabinoids could modify LPS-induced PG production, uterine explants were incubated for 24 h in the presence of LPS (1 μg/ml) induced PGE2 and PGF2α production in vitro. To evaluate whether endogenous cannabinoids could modify LPS-induced PG production, uterine explants were incubated for 24 h in the presence of LPS (1 μg/ml), LPS plus AM251 (CBl receptor antagonist) or LPS plus SR144528 (CB2 receptor antagonist) and PGE2 and PGF2α levels were assessed by RIA. LPS-induced PGE2 synthesis was observed to be significantly increased when uterine
explants were incubated with LPS and AM251 (10 nM) (Figure 1A). Nevertheless, incubation of the endotoxin with the CB2 receptor antagonist (10 nM) had no effect on PGE2 increased levels due to LPS in the same tissue (Figure 1A). Higher concentrations of the CB2 receptor antagonist were also used with the same results (data not shown). On the other hand, LPS-induced PGF2α synthesis was partially but significantly decreased when uterine explants were incubated both with LPS and AM251 (10 nM) or with LPS and SR144528 (100 nM) (Figure 1B). PG levels remained unchanged when tissues were incubated either with AM251 or SR144528 alone. These findings suggest that endocannabinoids could exert opposite effects on PGE2 and PGF2α biosynthesis, by inhibiting PGE2 production and increasing PGF2α levels.

Among endocannabinoids AEA has been reported to regulate PG production in several tissues [12,13]. Mitchell et al. have shown that AEA significantly reduced PGE2 production in human deciduous tissue [11]; on the other hand, Someya et al. showed that AEA stimulates PGF2α formation in PC12 cells [13]. Regarding LPS-induced PG production is mediated by endocannabinoids and considering that AEA could be involved in this process, we next analyzed if exogenous AEA could modify PG biosynthesis. First, uterine explants were incubated with methanandamide [m-AEA, a stable synthetic AEA analog] and PGE2 and PGF2α levels were determined by RIA. We observed that explants incubated with m-AEA 100 nM showed a significantly increase of PGF2α levels (Figure 2B), while PGE2 levels were significantly reduced (Figure 2A). We also used an inhibitor of AEA degradation (URB597, 1 uM) with the same results (Figure 2A and B). To test whether AEA mediates LPS-induced PG production, uterus was incubated in the presence of LPS (1 μg/ml) plus m-AEA (100 nM) or LPS (1 μg/ml) plus URB597 (1 uM) for 24 h and PG levels were assessed by RIA. Figure 2A shows that PGE2 production induced by LPS was partially but significantly decreased when tissues were incubated either with LPS plus m-AEA or with LPS plus URB597. On the other hand, PGF2α production was significantly increased when tissues were incubated with LPS plus m-AEA (figure 2B).

**Effect of LPS on CB1 and CB2 mRNA and Protein Levels**

The data showed in figure 1 suggest a possible involvement of CB1 and CB2 on PG production upon stimulation with LPS. In

![Figure 6. Effect of AEA on COX-2 expression.](https://doi.org/10.1371/journal.pone.0039532.g006)
order to determine the effect of LPS on CB1 and CB2 expression in uterine explants, tissues were incubated for 24 h in the presence of LPS (1 μg/ml) and mRNA and protein levels were assessed. We observed the presence of both CB receptors, CB1 and CB2, in pregnant murine uterus. Furthermore, our results show that the endotoxin caused an increase in CB1 expression (Figure 3A and B) while CB2 levels remained unchanged (Figure 3C and D).

LPS-induced PG Synthesis and Cyclooxygenase (COX) Expression is Mediated by Endocannabinoids

Since PG synthesis first involves the release of arachidonic acid which is converted to prostaglandin H2 (PGH2) by cyclooxygenase 1 (COX-1) or cyclooxygenase 2 (COX-2) enzymes, uterine explants were incubated for 24 h in the presence of LPS (1 μg/ml) alone, LPS plus AM251 (10 nM) or LPS plus SR144528 (100 nM) and COX-1 and COX-2 mRNA and protein levels were assessed. RT-PCR and western-blot analysis indicated that LPS significantly increased the expression of COX-2, whereas COX-1 mRNA and protein levels remained unchanged (Figures 4A and B). On the other hand, LPS-induced COX-2 expression (both mRNA and protein) was observed to be partially but significantly decreased when uterine explants were incubated either with LPS and AM251 or with LPS and SR144528 (Figure 4A and B). COX

Figure 7. AEA increases COX-2 activity. Uterine explants were incubated with m-AEA (100 nM) or URB597 (1 μM) for 24 h and COX-2 enzyme activity was determined by measuring the disappearance of the radiolabelled substrate [14C]-AA. Enzyme activity is reported as nmol of disappeared [14C]-AA/mg protein/h. ANOVA test. a, p < 0.05 vs control; b, p < 0.01 vs control; n = 4. doi:10.1371/journal.pone.0039532.g007

Figure 8. Endocannabinoids modulate mPGES-1 mRNA levels. Densitometric analysis and mRNA expression of PGES isoforms. Uterine explants were incubated with LPS alone (1 μg/ml), LPS plus AM251 (10 nM) or LPS plus SR144528 (10 nM) for 24 h. A) One representative gel is shown. B) Densitometric analysis. ANOVA test. a, p < 0.001 vs control; b, p < 0.01 vs LPS; c, p < 0.001 vs LPS. n = 5. doi:10.1371/journal.pone.0039532.g008
levels remained unchanged when tissues were incubated with AM251 or SR144528 alone (data not shown).

Regarding these results, we next evaluated COX-2 activity by measuring the disappearance of the radiolabelled substrate [14C]-arachidonic acid. Figure 5 shows a 3-fold increase in COX-2 activity when tissues were incubated with LPS alone. Moreover, LPS-induced COX-2 activity was partially but significantly decreased when uterine explants were incubated either with LPS and AM251 or with LPS and SR144528. These findings suggest that endocannabinoids mediate LPS-induced COX-2 activity.

As stated before, several lines of evidence indicate that both, cannabinoids and AEA, stimulate arachidonic acid (AA) release in several tissues [14,15,16]. Thus, we next analyzed if exogenous AEA could modify COX-1 and COX-2 mRNA and protein levels. RT-PCR and western-blot analysis indicated that m-AEA significantly increased the expression of COX-2, whereas COX-1 mRNA and protein levels remained unchanged (Figures 6A and B). We next evaluated COX-2 activity. Figure 7 shows a 2-fold increase in COX-2 activity when tissues were incubated either with m-AEA (100 nM) or URB597 (1 uM) alone. These results suggest that AEA could be mediating, at least partially, LPS-induced COX-2 activity.

**AEA: a Possible Role in PGE2 Metabolism**

Our data show that AEA-induced PGF2α production correlates with the increased expression and activity of COX-2. Nevertheless, decreased production of PGE2 induced by AEA is not explained by an augmentation of COX-2 expression and activity. In this sense, PGE2 levels could fluctuate due to inhibition of its synthesis, an increased catabolism or both. PGE2 synthesis involves the activity of PGE synthase (PGES) which catalyzes conversion of COX-derived PGH2 to PGE2. So far, three different isoforms have been identified with the capacity to synthesize PGE2 [26]. These include membrane-associated (or microsomal) PGE2 synthase-1 and -2 (mPGES-1 and mPGES-2, respectively), and
cytosolic PGES (cPGES). Regarding this evidence, we first investigate whether endogenous cannabinoids could modify the expression of these enzymes and thus, we evaluated the effect of LPS plus CB receptor antagonists on uterine mRNA levels of PGES isoforms. Our results show that only mPGES-1 mRNA levels were significantly increased when uterine explants were incubated in the presence of LPS (Figure 8B). Moreover, LPS-induced mPGES-1 expression was observed to be significantly increased when uterine explants were incubated with LPS and AM251 (10 nM) or with LPS and the CB2 receptor antagonist (100 nM) (Figure 8B). We next evaluated if endocannabinoids could modulate mPGES-1 protein levels. Western blot analysis showed that LPS-induced mPGES-1 expression was significantly increased when tissues were incubated with LPS plus CB receptor antagonists (Figure 9).

As we mentioned before, AEA reduces PGE2 production in human decidual tissue [11]. Considering that LPS-induced mPGES-1 expression is mediated by endocannabinoids and regarding AEA could be involved in this process, we next analyzed if exogenous AEA could modify the expression of mPGES-1. Our results show that both mPGES-1 mRNA and protein levels were significantly reduced when uterine explants were incubated in the presence of m-AEA (100 nM) (Figure 10A and B, respectively).

Regarding the very small decline in mPGES-1 mRNA (although significant) and the substantial decrease in mPGES-1 protein we decided to make a more quantitative approach by performing a real time PCR at early times. We assessed mPGES-1 mRNA levels when uterine explants were incubated either for 3 h or 6 h in the presence of m-AEA (100 nM). We observed that mPGES-1 mRNA levels remained unchanged after 3 h incubation in the presence of m-AEA. Nevertheless, uterine explants incubated for 6 h in the presence of the synthetic analog reduced mPGES-1 mRNA levels up to nearly 25% (Figure 11).

We next investigate whether exogenous AEA could modify the production of PGE2 by modulating PGES activity. Thus, uterine explants were incubated in the presence of m-AEA (100 nM) alone or m-AEA plus indomethacin (INDO 1 μM [27], a non-selective COX inhibitor) and conversion of PGH2 to PGE2 was assessed by RIA. Incubation with INDO prevents COX-derived PGE2 de novo synthesis from AA release. We observed that m-AEA significantly decreased PGES activity (Figure 12). These findings suggest that AEA could be downregulating uterine PGE2 levels by inhibiting its synthesis.

Another enzyme which may influence the level and biological activity of PGs is 15-hydroxyprostaglandin dehydrogenase (15-PGDH). It is responsible for converting PGs into biologically inactive 15-keto derivative [28]. We first studied the effect of AEA on 15-PGDH mRNA and protein levels in uterine explants incubated with m-AEA 100 nM for 24 h. RT-PCR and western-blot analysis indicated that m-AEA did not modify 15-PGDH expression (data not shown). Next, we studied whether AEA could modify the production of PGE2 metabolite (PGEM, biologically inactive). In this sense, PGEM quantification was assessed in culture supernatants by Cayman’s PGE metabolite EIA kit as described in the Materials and methods section. At the same time, PGE2 levels were assessed in the same sample by RIA. Our results

Figure 11. Quantitative real-time PCR analysis of mPGES-1 expression. Uterine explants were incubated without/with m-AEA (100 nM) for 3 h and 6 h and then subjected to qPCR analysis. Data was normalized against β-actin and mPGES-1 mRNA levels under control conditions (no m-AEA) were set to 1 (dotted line). Experiments were independently run three times. In each experiment, cDNA samples were performed in triplicate. Student t Test. a, p<0.05 vs control. n = 9.
doi:10.1371/journal.pone.0039532.g011

Figure 12. Effect of AEA on PGE synthase activity. Uterine explants were incubated with m-AEA (100 nM), INDO (1 μM) or m-AEA plus INDO for 24 h. Results were expressed as pg PGE2/mg protein/h. ANOVA Test. a, p<0.001 vs control or INDO. n=4. PGE2 levels were assessed by RIA.
doi:10.1371/journal.pone.0039532.g012
show that m-AEA (100 nM) significantly decreased PGE$_2$ levels corroborating the results showed before, and at the same time, significantly increased PGEM production in the same samples (Figure 13).

In several tissues, including decidua and fetal membranes, PGE$_2$-9-ketoreductase (9-KPR) converts PGE$_2$ into PGF$_{2\alpha}$ thus regulating PGE$_2$/PGF$_{2\alpha}$ ratio in these tissues [29,30]. Therefore, we studied the effect of AEA on 9-KPR activity in uterine explants incubated with m-AEA 100 nM for 24 h. We found that although we detected 9-KPR activity in the uterus of pregnant mice m-AEA did not modify it in this tissue (data not shown).

These findings suggest a possible role of AEA on PGE$_2$ metabolism and, in this sense, AEA could be downregulating uterine PGE$_2$ levels not only by inhibiting its synthesis but also by increasing its degradation.

Discussion

Embryonic resorption induced by sepsis is viewed as a serious obstetric problem but it may also be seen from an evolutionary perspective as a pathophysiological mechanism to protect the maternal reproductive potential by expelling infected material. Prostaglandins are potent stimulators of myometrial contractility [31] and are used clinically to induce abortion and stimulate parturition [4]. Particularly, both PGE$_2$ and PGF$_{2\alpha}$ stimulate myometrial contractility and are produced during labor by gestational tissues [32,33]. Our previous results showed that in vivo administration of LPS increased PGE$_2$ and PGF$_{2\alpha}$ production in the uterus of early pregnant mice. Also, we have observed that, in mice challenge with LPS, the in vivo administration of COX inhibitors prevented LPS-induced ER [1]. Collectively, these data suggest that although PGs are important paracrine regulators of uterine function in normal pregnancies, in an inflammatory setting such as sepsis, PGs have deleterious effects.

On the other hand, several lines of evidence show that LPS increases AEA levels [8,9] and also that AEA modulates prostaglandin production in different tissues [11,12,13].

Based on the above evidence, we hypothesized that LPS-induced PG synthesis is mediated by endocannabinoids. Our results showed that endocannabinoids are involved in LPS-induced PG biosynthesis and also had different effects on PG biosynthetic pathways. While LPS-induced PGF$_{2\alpha}$ production was partially abrogated through both CB1 and CB2 receptors, LPS-induced PGE$_2$ production was significantly increased when uterine explants were incubated with LPS plus a selective CB1 inhibitor (AM251) compared to explants incubated with LPS alone. On the other hand, CB2 receptor appeared not to be involved in LPS-induced PGE$_2$ production. Considering that other groups’ findings show that, among endocannabinoids, AEA modulates PG biosynthetic pathways differently [11,12,13] we next evaluated whether AEA mediates LPS-induced PG production. Thus, we assessed uterine PGE$_2$ and PGF$_{2\alpha}$ production in the presence of LPS plus a stable synthetic analog of AEA called m-AEA, or LPS plus an inhibitor of AEA degradation, URB597. Our findings showed that PGE$_2$ production induced by LPS was partially but significantly decreased when tissues were incubated either with LPS plus m-AEA or with LPS plus URB597. On the other hand, PGF$_{2\alpha}$ production was significantly increased when tissues were incubated with LPS plus m-AEA. Together, these results suggest that AEA may be involved in LPS-induced PG production and that it modulates PG biosynthetic pathways differently for each PG. This is in accordance with the findings from other groups where it has been reported that AEA stimulates PGF$_{2\alpha}$ formation in PC12 cells [13] and also exerts a significant reduction in PGE$_2$ production in human decidual tissue [11]. We have also shown that endocannabinoids mediate LPS-induced COX-2 activity, mRNA and protein expression and AEA could be involved in this process. Although we showed that m-AEA had opposite effects on PGE$_2$ and PGF$_{2\alpha}$ production, our previous results demonstrate that LPS induced the increase of PGs both in vivo [1] and in vitro. Also, LPS-induced COX-2 activity and expression was partially but significantly decreased when tissues were incubated with LPS and CB receptor antagonists. Taking this into consideration, it seems that AEA partially mediates LPS-induced PG production and therefore, we cannot rule out that other mechanisms (and/or other endocannabinoids) may be involved in this process.

On the other hand, we detected CB1 expression in the uterus of pregnant mice and also we reported for the first time the presence of CB2 in this tissue, contrary to other groups’ findings that suggest the absence of CB2 both in the oviduct and in the uterus of mice [34,35]. Moreover, we have shown that LPS modulated CB1 mRNA and protein expression although CB2 levels remained unchanged. This is in accordance with the work of Matias et al. [36] and Do et al. [37] where they reported that LPS modulates CB1 and CB2 expression in dendritic cells.

Taking into consideration that AEA-induced PGF$_{2\alpha}$ production correlates with an increased expression and activity of COX-2 but decreased production of PGE$_2$ induced by AEA is not in accordance with the regulation of COX-2 levels, we investigated whether endogenous cannabinoids could modify the expression of
the three different isoforms with capacity to synthesize PGE₂ identified so far, m-PGES-1, mPGES-2 and cPGES. Our results showed that only mPGE-1 expression was induced in the presence of LPS. This is in accordance with previous reports where a preferential coupling of COX-2 with mPGE-1 is shown in various reports [30] and its expression is induced by pro-inflammatory mediators [23]. Moreover, LPS-induced mPGE-1 expression was observed to be significantly increased when uterine explants were incubated with LPS and CB receptor antagonists suggesting the participation of endocannabinoids in this process.

We also investigated the effect of exogenous AEA on different steps of PGE₂ metabolic pathway. Our results showed that AEA downregulated PGE₂ levels most likely due to inhibition of its synthesis and upregulation of its degradation. We have observed that AEA significantly reduced mPGE-1 mRNA and protein levels, which probably contribute to the decrease of PGE₂ synthesis. These results are in accordance with Navarrete et al. [39] who reported that N-arachidonoyl-dopamine (NADA, another member of the endocannabinoid family) is a potent inhibitor of PGE₂ production through a mechanism that involves reduction in the synthesis of mPGE-1 protein in LPS-activated microglia. Taking this evidence into consideration we cannot rule out that other endogenous CB₁ and CB₂ agonists (such as NADA and 2-AG, 2-arachidonoyl-glycerol) could also be involved in the action of LPS. The fact that AEA reduces PGE₂ levels could be considered as an anti-inflammatory effect of this endocannabinoid.

On the other hand, although several groups have reported that uterine 15-PGDH activity is regulated by progesterone during the entire pregnancy [40,41] this is the first time that an endocannabinoid modulation of PGE₂ degradation is demonstrated.

The above reported data and our previous results [1] show that LPS induces PGE₂ and PGF₂α production. Nevertheless, it is possible that PGE₂/PGF₂α ratio more than the concentration reached by each of these PGs, may play a critical role in many biological functions, such as contractility. In fact, the altered ratio of PGE₂/PGF₂α was described as one of the factors involved in the retention of fetal membranes in cattle [42,43,44]. In our case, where we studied PGE₂ and PGF₂α participation in LPS-induced embryonic resorption [1] there always seemed to be a predominance of PGF₂α over PGE₂. The difference in the amount of PGE₂ and PGF₂α that reaches the uterus may play a role in the control of myometrial contractility. PGF₂α mediates myometrial contractions associated with the onset of labor [32]. Although it is less clearly established, PGE₂ is thought to exert the opposite action and favor the establishment of pregnancy. Moreover, Slater et al. [43] have reported that PGE₂ has anti-inflammatory and relaxatory effects on human myometrial smooth muscle.

Other groups have shown that LPS increases AEA production [9,9] and in spite of the fact that we did not measure direct changes in endocannabinoid concentrations in culture media after LPS challenge, the use of CB specific antagonists and the use of m-AEA allow us to hypothesize that AEA could be involved in the mechanisms implicated in LPS-induced embryonic resorption. We propose that AEA participates in LPS-induced COX-2 expression and activity, increasing PGF₂α levels and downregulating PGE₂ production modulating PG’s ratio in this tissue. AEA inhibitory effect on PGF₂α production may be compensated by LPS stimulus (which may involve other endogenous CB receptor agonists and/or other mechanisms) and the final outcome is likely to be a PGE₂/PGF₂α ratio that would favor myometrial contractions which in turn contribute to fetal expulsion in an inflammatory setting.

In conclusion, this study suggests that AEA acts as a procontractility agent modulating the production of PGs induced by LPS. This and our previous results showing that AEA participates in the increase of nitric oxide synthesis induced by LPS [10] demonstrate that this endocannabinoid could contribute to the mechanisms associated with pathological reproductive events such as septic abortion.

Acknowledgments

The authors gratefully acknowledge Sanofi-Aventis for kindly providing SR144528.

Author Contributions

Conceived and designed the experiments: CAV AMF. Performed the experiments: CAV JA MC AIS MLW. Analyzed the data: CAV JA AMF. Contributed reagents/materials/analysis tools: AMF. Wrote the paper: CAV.
10. Kubo T, Kubota T, Kamei D, Murakami M, Kudo I, et al. (2005) Change in PGESs in microsomal PGES-1 knock out mice in a preterm delivery model. J Endocrinol 187: 339–345.

11. Wang F, Wang J, Liu D, Su Y (2010) Normalizing genes for real-time polymerase chain reaction in epithelial and nonepithelial cells of mouse small intestine. Anal Biochem 399: 211–17.

12. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-DDCt method. Methods 25: 402–8.

13. Vercelli CA, Aisemberg J, Billi S, Wolfson ML, Franchi AM (2009) Endocannabinoid system and nitric oxide are involved in the deleterious effect of lipopolysaccharide on murine decidua. Placenta 30: 579–84.

14. Farina MG, Billi S, Sordelli MS, Ribeiro ML, Di Girolamo G, et al. (2006) Nitric oxide (NO) inhibits prostaglandin E2 9-ketoreductase (9-KPR) activity in human fetal membranes. Prostaglandins Other Lipid Mediat 79(3–4): 260–270.

15. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, et al. (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275(42): 32783–92.

16. Zerani M, Dall’Aglio C, Maranesi M, Gobberti A, Brecchia G, et al. (2007) Intraluteal regulation of prostaglandin F2α-induced prostaglandin biosynthesis in pseudopregnant rabbits. Reproduction 133: 1005–16.

17. Parthasarathy S, Wieland E, Steinberg D (1989) A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 86: 464–50.

18. Wiqvist N, Lindblom B, Wikland M, Wilhelmsson L (1983) Prostaglandins and lipoxygenase. A review. Lipids 18(12): 977–997.

19. Hansen HS (1976) 15-Hydroxyprostaglandin dehydrogenase. A review. Prostaglandins 12: 647–9.

20. Schlegel W, Krager S, Korte K, Mitchell MD, MacDonald PC, et al. (1986) Prostaglandin E2 9-ketoreductase activity in human decidua vera tissue. Placenta 7(4): 699–707.

21. Celli M, Leguizamon GF, Sordelli MS, Cervini M, Guadagnoli T, et al. (2008) Dual effect of anandamide on rat placenta nitric oxide synthase. Placenta 29: 679–87.

22. Schlegel W, Krager S, Korte K, Mitchell MD, MacDonald PC, et al. (1986) Prostaglandin E2 9-ketoreductase activity in human decidua vera tissue. Am J Obstet Gynecol 155(6): 1348–52.

23. Vane JR, Williams KI (1973) The contribution of prostaglandin production to contractions of the isolated uterus of the rat. Br J Pharmacol 48(4): 629–39.

24. Gu W, Rice GE, Thorburn GD (1990) Prostaglandin E2 and F2 alpha in midpregnant rat uterus and at parturition. Prostaglandins Leukot Essent Fatty Acids 40(1): 27–30.

25. Winchster SK, Imamura T, Gross GA, Muglia LM, Vogt SK, et al. (2002) Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. Endocrinology 143(7): 2593–2603.

26. Gross TS, Williams WF, Manspeaker JE, Lewis GS, Russel-Cohen E (1987) Bovine placental prostaglandin synthesis in vitro as it relates to placentation separation. Prostaglandins 34: 903–17.

27. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, et al. (2002) Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269: 3771–8.

28. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti P (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173: 2373–82.

29. Jaksobson PJ, Thorén S, Morgenstern R, Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96(13): 7220–5.

30. Vanarrete GM, Fiebich BL, de Viruesa AG, Hess S, de Oliveira AC, et al. (2009) Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin Eₙ and 8-iso-PGF₂₅ in primary glial cells. J Neurochem 109(2): 432–46.

31. Farina M, Ribeiro ML, Weismann G, Estevez A, Billi S, et al. (2004) Biosynthesis and catalysis of prostaglandin F₂ (α) are controlled by progesterone in the rat uterus during pregnancy. J Steroid Biochem Mol Biol 91: 211–8.

32. Winchester SK, Imamura T, Gross GA, Muglia LM, Vogt SK, et al. (2002) Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. Endocrinology 143(7): 2593–8.

33. Gross TS, Williams WF, Manspeaker JE, Lewis GS, Russeck-Cohen E (1987) Bovine placental prostaglandin synthesis in vitro as it relates to placentation separation. Prostaglandins 34: 903–17.

34. Das SK, Paria BC, Chakraborty I, Dey SK (1995) The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci USA 92: 4332–6.

35. Wang H, Guo Y, Wang D, Kinsley PJ, Marnett LJ, et al. (2004) Aberrant cannabinoid signaling impairs ovudinal transport of embryos. Nat Med 10: 1074–80.

36. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, et al. (2002) Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269: 3771–8.

37. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti P (2004) Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 173: 2373–82.

38. Jaksobson PJ, Thorén S, Morgenstern R, Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96(13): 7220–5.

39. Vanarrete GM, Fiebich BL, de Viruesa AG, Hess S, de Oliveira AC, et al. (2009) Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin Eₙ and 8-iso-PGF₂₅ in primary glial cells. J Neurochem 109(2): 432–46.

40. Farina M, Ribeiro ML, Weismann G, Estevez A, Billi S, et al. (2004) Biosynthesis and catalysis of prostaglandin F₂ (α) are controlled by progesterone in the rat uterus during pregnancy. J Steroid Biochem Mol Biol 91: 211–8.

41. Winchester SK, Imamura T, Gross GA, Muglia LM, Vogt SK, et al. (2002) Coordinate regulation of prostaglandin metabolism for induction of parturition in mice. Endocrinology 143(7): 2593–8.

42. Gross TS, Williams WF, Manspeaker JE, Lewis GS, Russeck-Cohen E (1987) Bovine placental prostaglandin synthesis in vitro as it relates to placentation separation. Prostaglandins 34: 903–17.

43. Slama H, Vaillancourt D, Goff AK (1993) Metabolism of arachidonic acid by inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 96(13): 7220–5.

44. Farina M, Ribeiro ML, Weismann G, Estevez A, Billi S, et al. (2004) Biosynthesis and catalysis of prostaglandin F₂ (α) are controlled by progesterone in the rat uterus during pregnancy. J Steroid Biochem Mol Biol 91: 211–8.